Zelicapavir | CAS#2070852-76-3 | nanomolar inhibitor | RSV-A | RSV-B

MedKoo Cat#: 140261 | Name: Zelicapavir

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zelicapavir, also known as EDP-938, is a nanomolar inhibitor of both RSV-A and RSV-B activity. EDP-938 is differentiated from RSV fusion inhibitors as the N-protein inhibitor targets the virus’ replication machinery and has demonstrated a high barrier to resistance in vitro. In preclinical studies, EDP-938 maintained antiviral potency across all clinical isolates tested and was active against viral variants resistant to other mechanisms.

Chemical Structure

Zelicapavir

CAS#2070852-76-3

Theoretical Analysis

MedKoo Cat#: 140261

Name: Zelicapavir

CAS#: 2070852-76-3

Chemical Formula: C27H22F3N7O3

Exact Mass: 549.1736

Molecular Weight: 549.51

Elemental Analysis: C, 59.02; H, 4.04; F, 10.37; N, 17.84; O, 8.73

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Zelicapavir; EDP-938; EDP938; EDP 938

IUPAC/Chemical Name

(3S)-3-({5-[3-(morpholin-4-yl)-5-(trifluoromethyl)pyridin-2-yl]- 1,3,4-oxadiazol-2-yl}amino)-5-phenyl-1,3-dihydro-2H-1,4- benzodiazepin-2-one

InChi Key

VGGNPZNYTJXPEW-HSZRJFAPSA-N

InChi Code

InChI=1S/C27H22F3N7O3/c28-27(29,30)17-14-20(37-10-12-39-13-11-37)22(31-15-17)25-35-36-26(40-25)34-23-24(38)32-19-9-5-4-8-18(19)21(33-23)16-6-2-1-3-7-16/h1-9,14-15,23H,10-13H2,(H,32,38)(H,34,36)/t23-/m1/s1

SMILES Code

O=C1NC2=CC=CC=C2C(C3=CC=CC=C3)=N[C@@H]1NC4=NN=C(C5=NC=C(C(F)(F)F)C=C5N6CCOCC6)O4

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 549.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Reina J, Iglesias C. EDP-938, un nuevo antiviral con actividad inhibidora frente a la nucleoproteína del virus respiratorio sincitial [EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus]. Rev Esp Quimioter. 2023 Feb;36(1):26-29. Spanish. doi: 10.37201/req/096.2022. Epub 2022 Nov 21. PMID: 36401806; PMCID: PMC9910671. 2: Ahmad A, Eze K, Noulin N, Horvathova V, Murray B, Baillet M, Grey L, Mori J, Adda N. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge. N Engl J Med. 2022 Feb 17;386(7):655-666. doi: 10.1056/NEJMoa2108903. PMID: 35172056. 3: Rhodin MHJ, McAllister NV, Castillo J, Noton SL, Fearns R, Kim IJ, Yu J, Blaisdell TP, Panarese J, Shook BC, Or YS, Goodwin B, Lin K. EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog. 2021 Mar 15;17(3):e1009428. doi: 10.1371/journal.ppat.1009428. PMID: 33720995; PMCID: PMC7993833.